Business Context and Reporting Period
Oramed Pharmaceuticals Inc. filed this Form 8-K on August 2, 2016, reporting a material definitive agreement entered into on the same date. The filing concerns an amendment to a technology license agreement with Hefei Tianhui Incubator of Technologies Co. Ltd., effective retroactively as of July 24, 2016.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a contractual amendment.
Material Changes
The Company executed an amendment to the Amended and Restated Technology License Agreement dated December 21, 2015. The amendment replaces the Pre-Commercialization Plan (Exhibit C) and Subsequent Payment arrangements (Exhibit F2) to revise specific milestone terms and planning details. All other terms, including the aggregate maximum payments, remain unchanged.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the execution of the amended agreement.
Investor Verification Points
- Verify the specific revised milestone terms and planning details in the replaced Exhibit C and Exhibit F2.
- Confirm that the aggregate maximum payment obligations under the original December 2015 agreement remain in full force.
- Review the original December 28, 2015 Form 8-K to understand the baseline terms of the License Agreement.